EyePoint and Rallybio shake hands on collaboration; Shionogi expects billions for Covid antiviral pill — report
EyePoint Pharmaceuticals and Rallybio will be entering into a partnership.
The deal will look at the delivery of Rallybio’s C5 inhibitor using EyePoint’s tech for intraocular drug delivery, dubbed Durasert. The research will focus on geographic atrophy, an advanced form of macular degeneration that can eventually lead to vision loss.
Both companies also intend to expand upon the collaboration following the initial research work. However, no financial details have been given yet. In a release, Rallybio CEO Stephen Uden said that the use of C5 inhibitors has already shown “great promise.” While Jay Duker, president and COO of EyePoint, said that the collaboration hopes to use the technology to provide a more “desirable option” for patients — as the current therapy is injected every one to two months.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters